RELATIVITY 047 is the first randomized phase III study to validate inhibition of the LAG-3 immune checkpoint as a therapeutic strategy for patients with advanced melanoma. The results demonstrated a progression-free survival (PFS) benefit of the combination of nivolumab and relatlimab in the first-line treatment of advanced melanoma.
The prognosis of this type of cancer, as explained by oncologist Natália Ferreira Vaz, from Grupo Oncoclínicas in Belo Horizonte, can be considered good if detected in its initial phase: “The disease is classified as localized when there is no sign of disease dissemination, with five-year survival rates of 99%; is a regional disease when the tumor has spread to nearby structures or lymph nodes, with a 5-year survival rate of 65%, and considered distant disease when the tumor has spread to other organs, with a 5-year survival rate of 25% ”. According to the oncologist, despite the higher incidence of grade 3 and 4 adverse events in the combination group, the study showed an apparently favorable tolerance profile for this arm, with a discontinuation rate of less than 15%. It is important to remember that nivolumab is a medication already available in Brazil, whereas relatlimab is not yet. Access our website and read the full article with all the details of this study.